Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 169 member B, pseudogene (FAM169BP) is classified as a transcribed unitary pseudogene. Pseudogenes are noncoding genomic DNA sequences derived from protein-coding genes that have lost their protein-coding ability due to mutations but can sometimes be transcribed into RNA. Generally, pseudogenes are regarded as nonfunctional "genomic relics," though a subset of pseudogenes may influence gene regulation through RNA-mediated effects, such as serving as miRNA decoys or producing regulatory RNAs that modulate the expression of related coding genes[3]. However, FAM169BP does not have any reported known regulatory or disease-linked biological activity and is not recognized as a therapeutic target[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 169 member B, pseudogene (FAM169BP).